A Phase 1, Open-Label, Multiple-Dose, Dose-Escalation Study of MDX-1342 in Patients With CD19-Positive Refractory/Relapsed Chronic Lymphocytic Leukemia.

Trial Profile

A Phase 1, Open-Label, Multiple-Dose, Dose-Escalation Study of MDX-1342 in Patients With CD19-Positive Refractory/Relapsed Chronic Lymphocytic Leukemia.

Completed
Phase of Trial: Phase I

Latest Information Update: 21 May 2013

At a glance

  • Drugs MDX 1342 (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Jan 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 26 Jun 2009 Planned end date changed from Sep 2009 to Mar 2011 as reported by ClinicalTrials.gov.
    • 10 Jul 2008 Results are expected in 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top